α-Glucosidase-IN-21 (Compound 2B) is a highly potent, orally bioavailable α-glucosidase inhibitor with an IC50 value of 2.62 μM, demonstrating remarkable anti-diabetic properties [1].

α-Glucosidase-IN-21 (Compound 2B), administered orally at 10 and 20 mg/kg daily for four weeks, demonstrates anti-diabetic efficacy in male Wistar albino rats (170-200 g) with Streptozocin-induced diabetes. This compound significantly reduces serum glucose levels post-glucose administration (3 g/kg, orally) and shows no mortality in mice at 2000 mg/kg over two weeks. In addition, α-Glucosidase-IN-21 effectively decreases blood glucose levels, counteracts Streptozocin-induced weight loss, and exhibits antihyperlipidemic properties by notably lowering serum biomarkers in the diabetic rat model.